Important Information
If you are interested in applying for this study, please:
- Read the study description and study information document
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability.
Study Description
New Zealand Clinical Research is trialling an
investigational medication in adults who have
high cholesterol and have had, or are at risk of
having, a major cardiovascular event, such as a
heart attack or stroke.
Researchers want to learn about:
• how the investigational medication works
to lower cholesterol compared with a
placebo, which looks like the investigational
medication but does not contain active
ingredients
• the safety of the investigational medication
• whether the investigational medication can
reduce cardiovascular events
The investigational medication is a type of
cholesterol medication called a PCSK9 inhibitor.
The currently approved PCSK9 inhibitors are
taken as an injection, but the PCSK9 inhibitor
being tested in this study is a tablet that you
swallow.
It is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
This study (MK-0616-015) is being funded by Merck Sharp & Dohme (New Zealand) Limited (MSD) and has been approved by the Health and Disability Ethics Committee.
Requirements
- Males and females
- 18 years or older
- History of cardiovascular disease OR;
- High risk of cardiovascular disease event defined as:
- History of multivessel disease, prior stroke, carotid artery stenosis OR;
- Diabetes, daily insulin use OR;
- History of high blood pressure
What is Involved?
Study Duration: Up to 6 years
Scheduled Clinical Visits